#China #Shanghai #achondroplasia #Abbisko Therapeutics #ABSK061

Abbisko Therapeutics Achieves Key Milestone for ABSK061

On March 30, 2026, Abbisko Therapeutics Co., Ltd., listed on the Hong Kong Stock Exchange with the code 02256.HK, announced a significant advancement in treating achondroplasia in children. The U.S. Food and Drug Administration (FDA) has granted its Investigational New Drug (IND) application clearance for ABSK061, a selective small-molecule inhibitor targeting the FGFR2 and FGFR3 receptors. This milestone follows the recent classifications of ABSK061 as both a Rare Pediatric Disease Designation (RPDD) and an Orphan Drug Designation (ODD) by the FDA, designed to expedite its clinical development.

ABSK061 is currently undergoing evaluation in a Phase II clinical trial aimed at understanding its safety, tolerability, and effectiveness for children affected by achondroplasia (ACH). The trial commenced with the dosing of its first patient in China in December 2025, with preliminary data results projected for release in the latter half of 2026. Abbisko has ambitious plans to include U.S. patients in this Phase II study, marking an essential step in its global development strategy for ABSK061.

Achondroplasia is a rare genetic disorder that leads to significant growth and development challenges due to mutations in the FGFR3 gene, which disrupt normal bone development. Current research has revealed that the pathogenesis of ACH is primarily driven by the abnormal activation of the FGFR3 pathway. Inhibition of this receptor presents a modern approach that could potentially improve treatment accuracy for patients diagnosed with ACH.

ABSK061, developed independently by Abbisko Therapeutics, has showcased strong inhibitory capabilities, favorable pharmacokinetics, and a promising safety profile based on preclinical research. It is specifically noted for its oral administration, offering considerable advantages in terms of treatment adherence and convenience, especially for pediatric patients. This positions ABSK061 as a highly anticipated therapeutic option for children and adolescents suffering from achondroplasia.

The innovative nature of ABSK061 stems from its selective action, which maintains potency against FGFR2 and FGFR3 while minimizing interactions with FGFR1—a common issue with previous generation pan-FGFR inhibitors that have faced regulatory hurdles due to side effects. By overcoming these limitations, ABSK061 aims to establish a wider therapeutic window, promising better clinical outcomes as a next-generation FGFR inhibitor.

In summary, Abbisko Therapeutics is forging ahead with ABSK061 in its quest to alleviate the developmental hurdles faced by children with achondroplasia. With ongoing clinical trials and regulatory backing, the company is optimistic about bringing this pioneering treatment to market. The upcoming data is eagerly anticipated not only by the company and its investors but also by families searching for effective therapies to improve the lives of children living with this challenging condition.

Reference: Savarirayan R, et al. International Consensus Statement on the diagnosis, multidisciplinary management and lifelong care of individuals with achondroplasia. Nat Rev Endocrinol. 2022 Mar;18(3):173-189.